Local pharmaceutical giant AbbVie is suing drug manufacturer BeiGene over allegedly stealing trade secrets to develop a competing cancer drug following the hiring of a longtime AbbVie research ...

In a lawsuit filed Friday, lawyers for AbbVie argued that BeiGene “enticed and encouraged” former AbbVie scientist Huaqing Liu, who’s named as a defendant in the case, to jump ship and share ...

Sept 9 (Reuters) - Pharmaceutical giant AbbVie (ABBV.N), opens new tab has sued cancer treatment maker BeiGene (6160.HK), opens new tab in Chicago federal court, accusing it of stealing trade ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study. In the Phase 3 ...

It’s as you were at the top of the TV drug ad spending table as AbbVie continues its 2024 domination as total spending across the top 10 pharma companies rebounds from its summer lull.

Vandana Singh TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades' TransDigm Group (TDG), BJ's Wholesale (BJ), VanEck Semiconductor ETF (SMH), and AbbVie (ABBV) were recommended as ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

AbbVie's nonprofit foundation is partnering with health care incubator Matter on a new accelerator to advance solutions to improve care for underserved communities. The AbbVie Foundation Health ...

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart ...

AbbVie plans to present the full results at medical conferences and expects additional trial data from TEMPO-2 by the end of 2024. Tavapadon is an investigational D1/D5 dopamine receptor partial ...